Avadel Pharmaceuticals Announces FDA Authorization to Import Tentatively-Approved LUMRYZ™ Ahead of Anticipated Final Approval Decision
March 22, 2023 07:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 22, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
March 21, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 21, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Pharmaceuticals Requests Final FDA Approval for LUMRYZ™ (sodium oxybate) extended-release oral suspension
March 02, 2023 07:00 ET
|
Avadel Pharmaceuticals plc
- Submitted amendment on March 1, 2023 to the LUMRYZ NDA seeking final FDA approval DUBLIN, Ireland, March 02, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 16, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
February 08, 2023 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 03, 2023 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Pharmaceuticals Announces Publication of Real-World Data Highlighting the Risk of Accidental Dosing Errors with Immediate-Release Twice-Nightly Oxybates
January 24, 2023 08:00 ET
|
Avadel Pharmaceuticals plc
- Adverse events were reported in patients who took the second, middle-of-the-night dose of immediate-release oxybate less than 2.5 hours after the first dose - DUBLIN, Ireland, Jan. 24, 2023 ...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
January 23, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2023 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
December 19, 2022 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation...